Native American Tribes Reach Major Opioid Settlement
INDIGENOUS RIGHTS, 7 Feb 2022
BBC News - TRANSCEND Media Service
Native American tribes have agreed a landmark settlement with major drug companies over the devastation caused by opioid addiction.
OxyContin medication on a pharmacy shelf in Provo, Utah.
Photograph: Bloomberg/Bloomberg via Getty Images
1 Feb 2022 – The tentative deal – with Johnson & Johnson and three major drug distributers – is worth $590m (£436m).
The companies had been accused of “knowingly pushing addictive drugs into vulnerable communities”.
A statement from Johnson & Johnson said it admitted no wrongdoing in the settlement.
The company said its actions promoting their pain medications was “appropriate and responsible”.
Distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, also agreed the terms today.
Payouts from the settlement will be available to the 574 federally-recognised tribes, including those that did not take part in the claims.
A total of $440m will be paid over the next seven years, on top of the $75m already promised to the Cherokee Nation.AmerisourceBergen said the deal would “expedite the flow of resources to communities impacted by the crisis”.
Native Americans have “suffered some of the worst consequences of the opioid epidemic of any population in the United States,” according to the court papers from the Tribal Leadership Committee.
“The burden of paying these increased costs has diverted scarce funds from other needs and has imposed severe financial burdens on the tribal plaintiffs,” it said.
Tags: Drugs, Indigenous Rights, Justice, Native Americans, Native cultures, Opioids, Psychiatric disorders, USA
DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.